EU assesses GSK-Vir COVID-19 antibody therapy for authorisation

European health regulator said on Thursday it was assessing a marketing authorisation application for GSK-Vir Biotechnology's, monoclonal antibody treatment for COVID-19 and could give its opinion within two months. The drug, sotrovimab, branded as Xevudy was already under a speedy review by the European Medicines Agency (EMA), and GSK's application makes the drug the fourth application currently under EU lenses for the treatment of COVID-19.